Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 4871-4881

  Rad, Seyed Mohammad Ali Hosseini ^a,b   Langroudi, Lida ^a   Kouhkan, Fatemeh ^a   Yazdani, Laleh ^b   Koupaee, Alireza Nouri ^a   Asgharpour, Sara ^a   Shojaei, Zahra ^a   Bamdad, Taravat ^b   Arefian, Ehsan ^a,c  

^a STEM CELL TECHNOLOGY RESEARCH CENTER   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Gene therapy; Oligodeoxynucleotide (ODN) decoy; Transcription factor decoy (TFD)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL PENETRATING PEPTIDE; COMPLEX DECOY OLIGONUCLEOTIDE; DNA; DNA DECOY; DOUBLE STRANDED RNA; GENE THERAPY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NANOPARTICLE; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE DECOY; RNA; RNA DECOY; RNA POLYMERASE II; SIMPLE DECOY OLIGONUCLEOTIDE; SMALL INTERFERING RNA; SPLICE SWITCHING OLIGONUCLEOTIDE; STAT3 PROTEIN; TRANSCRIPTION FACTOR DECOY; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; OLIGODEOXYRIBONUCLEOTIDE; TRANSCRIPTION FACTOR;

3' UNTRANSLATED REGION; APOPTOSIS; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CANCER GENE THERAPY; CHROMATIN IMMUNOPRECIPITATION; DNA MODIFICATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENE THERAPY; GENETIC DATABASE; GENETIC STABILITY; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MOLECULAR DYNAMICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OLIGONUCLEOTIDE BASED GENE THERAPY; PRIORITY JOURNAL; REVIEW; RNA ACTIVATION; RNA DEGRADATION; RNA INTERFERENCE; RNA METABOLISM; TRANSCRIPTION INITIATION SITE; TRANSLATION REGULATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; GENETIC TRANSCRIPTION; GENETICS; NEOPLASMS;

BINDING SITES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; NEOPLASMS; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; RNA INTERFERENCE; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84938215102     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3344-z     Document Type: Review

References (104)

1. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A. 2006;103:17337–42.
2. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol. 2007;3:166–73.
3. Schwartz JC, Younger ST, Nguyen NB, Hardy DB, Monia BP, Corey DR, et al. Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol. 2008;15:842–8.
4. Zheng L, Wang L, Gan J, Zhang H. Rna activation: promise as a new weapon against cancer. Cancer Lett. 2014;355:18–24.
5. Junxia W, Ping G, Yuan H, Lijun Z, Jihong R, Fang L, et al. Double strand RNA-guided endogeneous e-cadherin up-regulation induces the apoptosis and inhibits proliferation of breast carcinoma cells in vitro and in vivo. Cancer Sci. 2010;101:1790–6.
6. Mao Q, Li Y, Zheng X, Yang K, Shen H, Qin J, et al. Up-regulation of e-cadherin by small activating rna inhibits cell invasion and migration in 5637 human bladder cancer cells. Biochem Biophys Res Commun. 2008;375:566–70.
7. Chen Z, Place RF, Jia ZJ, Pookot D, Dahiya R, Li LC. Antitumor effect of dsRNA-induced p21(waf1/cip1) gene activation in human bladder cancer cells. Mol Cancer Ther. 2008;7:698–703.
8. Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, et al. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res. 2010;70:10182–91.
9. Portnoy V, Huang V, Place RF, Li LC. Small rna and transcriptional upregulation. Wiley Interdiscip Rev RNA. 2011;2:748–60.
10. Rossi JJ. Transcriptional activation by small RNA duplexes. Nat Chem Biol. 2007;3:136–7.
11. Zamecnik PC, Stephenson ML. Inhibition of rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978;75:280–4.
12. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11:125–40.
13. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase ii study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:4247–54.
14. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein b synthesis inhibitor, for lowering of ldl cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
15. Calin GA, Croce CM. Microrna signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.
16. Rad SMAH, Bavarsad MS, Arefian E, Jaseb K, Shahjahani M, Saki N. The role of micrornas in stemness of cancer stem cells. Oncol Rev. 2013;7:e8.
17. Mobarra N, Shafiee A, Rad SM, Tasharrofi N, Soufi-Zomorod M, Hafizi M, Movahed M, Kouhkan F, Soleimani M. Overexpression of microrna-16 declines cellular growth, proliferation and induces apoptosis in human breast cancer cells. In Vitro Cell Dev Biol Anim. 2015. doi:10.1007/s11626-015-9872-4.
18. Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen JS, et al. Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther. 2014;25:587–98.
19. Bauman J, Jearawiriyapaisarn N, Kole R. Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides. 2009;19:1–13.
20. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med. 2011;364:1513–22.
21. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer avi-4658 in duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8:918–28.
22. Brown M, Figge J, Hansen U, Wright C, Jeang KT, Khoury G, et al. Lac repressor can regulate expression from a hybrid SV40 early promoter containing a lac operator in animal cells. Cell. 1987;49:603–12.
23. Hu MC, Davidson N. The inducible lac operator-repressor system is functional in mammalian cells. Cell. 1987;48:555–66.
24. Friedman AD, Triezenberg SJ, McKnight SL. Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus. Nature. 1988;335:452–4.
25. Trono D, Feinberg MB, Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell. 1989;59:113–20.
26. Wang XF, Calame K. Sv40 enhancer-binding factors are required at the establishment but not the maintenance step of enhancer-dependent transcriptional activation. Cell. 1986;47:241–7.
27. Park YG, Nesterova M, Agrawal S, Cho-Chung YS. Dual blockade of cyclic amp response element- (CRE) and AP-1-directed transcription by cre-transcription factor decoy oligonucleotide. gene-specific inhibition of tumor growth. J Biol Chem. 1999;274:1573–80.
28. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest. 2000;106:1071–5.
29. MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ. Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet. 2011;27:141–8.
30. Leung TH, Hoffmann A, Baltimore D. One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers. Cell. 2004;118:453–64.
31. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science. 1990;250:997–1000.
32. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of tar sequences renders cells resistant to human immunodeficiency virus replication. Cell. 1990;63:601–8.
33. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, et al. A gene therapy strategy using a transcription factor decoy of the e2f binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855–9.
34. Wang X, Liu Q, Hou B, Zhang W, Yan M, Jia H, et al. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells. PLoS One. 2013;8:e73942.
35. Rad SM, Bamdad T, Sadeghizadeh M, Arefian E, Lotfinia M, Ghanipour M. Transcription factor decoy against stem cells master regulators, nanog and oct-4: A possible approach for differentiation therapy. Tumour Biol. 2014. doi:10.1007/s13277-014-2884-y.
36. Seyed Mohammad Ali Hosseini Rad MSB, Arefian E, Kaveh Jaseb MS, Saki N. The role of micrornas in stemness of cancer stem cells. Oncol Rev. 2013;7:53–8.
37. Penolazzi L, Lambertini E, Aguiari G, del Senno L, Piva R. Modulation of estrogen receptor gene expression in human breast cancer cells: a decoy strategy with specific pcr-generated DNA fragments. Breast Cancer Res Treat. 1998;49:227–35.
38. Khaled AR, Butfiloski EJ, Sobel ES, Schiffenbauer J. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-kappaB expression and lymphocyte function. Clin Immunol Immunopathol. 1998;86:170–9.
39. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "Decoy" Strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res. 1998;82:1023–8.
40. Cooper Jr JA, Parks JM, Carcelen R, Kahlon SS, Sheffield M, Culbreth R. Attenuation of interleukin-8 production by inhibiting nuclear factor-kappab translocation using decoy oligonucleotides. Biochem Pharmacol. 2000;59:605–13.
41. Shibuya T, Takei Y, Hirose M, Ikejima K, Enomoto N, Maruyama A, et al. A double-strand decoy DNA oligomer for NF-kappaB inhibits TNFalpha-induced ICAM-1 expression in sinusoidal endothelial cells. Biochem Biophys Res Commun. 2002;298:10–6.
42. Gao H, Xiao J, Sun Q, Lin H, Bai Y, Yang L, et al. A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol. 2006;70:1621–9.
43. Dzau VJ, Horiuchi M. In vivo gene transfer and gene modulation in hypertension research. Hypertension. 1996;28:1132–7.
44. Tomita N, Kashihara N, Morishita R. Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease. Clin Exp Nephrol. 2007;11:7–17.
45. Jiang C, Xuan Z, Zhao F, Zhang MQ. Tred: A transcriptional regulatory element database, new entries and other development. Nucleic Acids Res. 2007;35:D137–40.
46. Carey MF, Peterson CL, Smale ST. Chromatin immunoprecipitation (chip). Cold Spring Harbor Protocols. 2009;2009:pdb. prot5279.
47. Penolazzi L, Lambertini E, Aguiari G, del Senno L, Piva R. Cis element 'decoy' against the upstream promoter of the human estrogen receptor gene. Biochim Biophys Acta. 2000;1492:560–7.
48. Fennewald SM, Scott EP, Zhang L, Yang X, Aronson JF, Gorenstein DG, et al. Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections. J Gen Virol. 2007;88:981–90.
49. Catimel B, Rothacker J, Nice E. The use of biosensors for microaffinity purification: an integrated approach to proteomics. J Biochem Biophys Methods. 2001;49:289–312.
50. Hellman LM, Fried MG. Electrophoretic mobility shift assay (EMSA) for detecting protein–nucleic acid interactions. Nat Protoc. 2007;2:1849–61.
51. Majumder S, Varadharaj S, Ghoshal K, Monani U, Burghes AH, Jacob ST. Identification of a novel cyclic amp-response element (CRE-ii) and the role of CREB-1 in the camp-induced expression of the survival motor neuron (SMN) gene. J Biol Chem. 2004;279:14803–11.
52. Gambari R. Biospecific interaction analysis: a tool for drug discovery and development. Am J Pharmacogenomics. 2001;1:119–35.
53. Gambari R, Feriotto G, Rutigliano C, Bianchi N, Mischiati C. Biospecific interaction analysis (BIA) of low-molecular weight DNA-binding drugs. J Pharmacol Exp Ther. 2000;294:370–7.
54. Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J Pharmacol Exp Ther. 1997;281:810–6.
55. Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cd-1 mice. Antisense Nucleic Acid Drug Dev. 1997;7:473–81.
56. Campbell JM, Bacon TA, Wickstrom E. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods. 1990;20:259–67.
57. Crooke ST. Progress in antisense technology: The end of the beginning. Methods Enzymol. 2000;313:3–45.
58. Phillips MI, Zhang YC. Basic principles of using antisense oligonucleotides in vivo. Methods Enzymol. 2000;313:46–56.
59. Uhlmann E, Peyman A, Breipohl G, Will DW. Pna: Synthetic polyamide nucleic acids with unusual binding properties. Angew Chem Int Ed. 1998;37:2796–823.
60. Mischiati C, Borgatti M, Bianchi N, Rutigliano C, Tomassetti M, Feriotto G, et al. Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappaB binding sites of the human immunodeficiency virus type 1 promoter. J Biol Chem. 1999;274:33114–22.
61. Borgatti M, Breda L, Cortesi R, Nastruzzi C, Romanelli A, Saviano M, et al. Cationic liposomes as delivery systems for double-stranded pna-DNA chimeras exhibiting decoy activity against NF-kappaB transcription factors. Biochem Pharmacol. 2002;64:609–16.
62. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A. 2000;97:5633–8.
63. Crinelli R, Bianchi M, Gentilini L, Magnani M. Design and characterization of decoy oligonucleotides containing locked nucleic acids. Nucleic Acids Res. 2002;30:2435–43.
64. Kubareva EA, Fedorova OA, Gottikh MB, Tanaka H, Malvy C, Shabarova ZA. NF-kappaB p50 subunit cross-linking to DNA duplexes, containing a monosubstituted pyrophosphate internucleotide bond. FEBS Lett. 1996;381:35–8.
65. Lindgren M, Hallbrink M, Prochiantz A, Langel U. Cell-penetrating peptides. Trends Pharmacol Sci. 2000;21:99–103.
66. Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA. Cell-penetrating peptides: application in vaccine delivery. Biochim Biophys Acta. 1805;2010:25–34.
67. Chauhan A, Tikoo A, Kapur AK, Singh M. The taming of the cell penetrating domain of the HIV Tat: Myths and realities. J Control Release. 2007;117:148–62.
68. El-Andaloussi S, Johansson H, Magnusdottir A, Jarver P, Lundberg P, Langel U. Tp10, a delivery vector for decoy oligonucleotides targeting the myc protein. J Control Release. 2005;110:189–201.
69. Buchanan KD, Huang SL, Kim H, McPherson DD, MacDonald RC. Encapsulation of NF-kappaB decoy oligonucleotides within echogenic liposomes and ultrasound-triggered release. J Control Release. 2009;141:193–8.
70. Takahashi T, Togo S, Kumamoto T, Watanabe K, Kubota T, Ichikawa Y, et al. Transfection of NF-kappaB decoy oligodeoxynucleotides into macrophages reduces murine fatal liver failure after excessive hepatectomy. J Surg Res. 2009;154:179–86.
71. Ohmori K, Takeda S, Miyoshi S, Minami M, Nakane S, Ohta M, et al. Attenuation of lung injury in allograft rejection using NF-kappaB decoy transfection-novel strategy for use in lung transplantation. Eur J Cardiothorac Surg. 2005;27:23–7.
72. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709–17.
73. McNamara 2nd JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006;24:1005–15.
74. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448:39–43.
75. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341–5.
76. Keates AC, Fruehauf JH, Xiang S, Parker PD, Li CJ. Cequent pharmaceuticals, inc.: the biological pitcher for RNAi therapeutics. Pharmacogenomics. 2007;8:867–71.
77. Xiang S, Fruehauf J, Li CJ. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol. 2006;24:697–702.
78. MacDiarmid JA, Mugridge NB, Weiss JC, Phillips L, Burn AL, Paulin RP, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell. 2007;11:431–45.
79. Timko BP, Whitehead K, Gao W, Kohane DS, Farokhzad O, Anderson D, et al. Advances in drug delivery. Annu Rev Mater Res. 2011;41:1–20.
80. Huang L, Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng. 2011;13:507–30.
81. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer–the time of truth. Lancet Oncol. 2002;3:672–83.
82. Coppelli FM, Grandis JR. Oligonucleotides as anticancer agents: From the benchside to the clinic and beyond. Curr Pharm Des. 2005;11:2825–40.
83. Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, Ohkawa T, et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res. 2003;289:27–35.
84. Kim KH, Lee WR, Kang YN, Chang YC, Park KK. Inhibitory effect of nuclear factor-kappab decoy oligodeoxynucleotide on liver fibrosis through regulation of the epithelial-mesenchymal transition. Hum Gene Ther. 2014;25:721–9.
85. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003;100:4138–43.
86. Liu M, Wang F, Wen Z, Shi M, Zhang H. Blockage of Stat3 signaling pathway with a decoy oligodeoxynucleotide inhibits growth of human ovarian cancer cells. Cancer Investig. 2014;32:8–12.
87. Zhang X, Liu P, Zhang B, Mao H, Shen L, Ma Y. Inhibitory effects of Stat3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo. Int J Mol Med. 2013;32:623–8.
88. Zhang X, Zhang J, Wang L, Wei H, Tian Z. Therapeutic effects of Stat3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer. 2007;7:149.
89. Sun X, Sui Q, Zhang C, Tian Z, Zhang J. Targeting blockage of Stat3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression. Mol Cancer Ther. 2013;12:2885–96.
90. Zhang X, Xiao W, Wang L, Tian Z, Zhang J. Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS One. 2011;6:e20965.
91. Ahn JD, Kim CH, Magae J, Kim YH, Kim HJ, Park KK, et al. E2f decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem Biophys Res Commun. 2003;310:1048–53.
92. Obama K, Kanai M, Kawai Y, Fukushima M, Takabayashi A. Role of retinoblastoma protein and E2F-1 transcription factor in the acquisition of 5-fluorouracil resistance by colon cancer cells. Int J Oncol. 2002;21:309–14.
93. Alper O, Bergmann-Leitner ES, Abrams S, Cho-Chung YS. Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: Protein kinase a downregulation and cytoplasmic export of CRE-binding proteins. Mol Cell Biochem. 2001;218:55–63.
94. Zhu X, Li Q, Li S, Chen B, Zou H. HIF-1alpha decoy oligodeoxynucleotides inhibit HIF-1alpha signaling and breast cancer proliferation. Int J Oncol. 2015;46:215–22.
95. Novak EM, Metzger M, Chammas R, da Costa M, Dantas K, Manabe C, et al. Downregulation of TNF-alpha and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor. Gene Ther. 2003;10:1992–7.
96. Membrino A, Cogoi S, Pedersen EB, Xodo LE. G4-DNA formation in the HRAS promoter and rational design of decoy oligonucleotides for cancer therapy. PLoS One. 2011;6:e24421.
97. El-Sagheer A. H BT. Synthesis, serum stability and cell uptake of cyclic and hairpin decoy oligonucleotides for TCF/LEF and GLI transcription factors. Int J Pept Res Ther. 2008;14:367–72.
98. Heilbronn R, Weger S. Viral vectors for gene transfer: Current status of gene therapeutics. Handb Exp Pharmacol. 2010:143-170.
99. Luo J, Luo Y, Sun J, Zhou Y, Zhang Y, Yang X. Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett. 2015;356:347–56.
100. Cooray S, Howe SJ, Thrasher AJ. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol. 2012;507:29–57.
101. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111–4.
102. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010;107:1864–9.
103. Brian P. Timko KW, Weiwei Gao. Advances in drug delivery. Ann Rev Mater Res. 2011.
104. Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, Pegtel DM. Exosomes: Fit to deliver small RNA. Commun Integr Biol. 2010;3:447–50.